在艾利利利公司考虑15亿欧元的收购报价后,阿比瓦克斯股价在2026年1月12日升22%. Abivax shares jumped 22% on Jan. 12, 2026, on takeover rumors after Eli Lilly considered a 15 billion euro bid.

2026年1月12日法国生物技术Abivax的股权大幅上升22%, 据报Eli Lilly正在准备150亿欧元的出价, Shares in French biotech Abivax surged 22% on January 12, 2026, after a report said Eli Lilly was preparing a 15 billion euro bid, citing positive Phase 3 results for Abivax’s ulcerative colitis drug obefazimod and growing takeover speculation. 股票升至120.80欧元,尽管两家公司都没有证实报告。 The stock rose to 120.80 euros, though neither company confirmed the report. Elilly在正式提出要约之前等待法国关于外国投资规则的监管指导。 Eli Lilly awaits French regulatory guidance on foreign investment rules before making a formal offer. Abivax的市场上限约为77.8亿欧元,分析家认为由于它有区别的口服疗法和在炎症区有限的晚期药物候选者,因此获得治疗的潜力很大。 Abivax’s market cap was about 7.78 billion euros, and analysts see strong acquisition potential due to its differentiated oral therapy and limited late-stage drug candidates in the inflammatory disease space.